Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

The Ariel Project: A Prospective Cohort Study of Maternal-Child Transmission of Human Immunodeficiency Virus Type 1 in the Era of Maternal Antiretroviral Therapy

Russell B. Van Dyke, Bette T. Korber, Edwina Popek, Catherine Macken, Susan M. Widmayer, Arlene Bardeguez, I. Celine Hanson, Andrew Wiznia, Katherine Luzuriaga, Richard R. Viscarello, Steven Wolinsky and Ariel Core Investigators
The Journal of Infectious Diseases
Vol. 179, No. 2 (Feb., 1999), pp. 319-328
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30117270
Page Count: 10
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
The Ariel Project: A Prospective Cohort Study of Maternal-Child Transmission of Human Immunodeficiency Virus Type 1 in the Era of Maternal Antiretroviral Therapy
Preview not available

Abstract

In a prospective cohort study, clinical and biologic factors that contribute to maternal-child transmission of human immunodeficiency virus type 1 (HIV-1) were studied. HIV-infected pregnant women and their infants were evaluated prospectively according to a standardized protocol. Of 204 evaluable women, 81% received zidovudine during their pregnancy. The infection rate among the 209 evaluable infants was 9.1%. By univariate analysis, histologic chorioamnionitis, prolonged rupture of membranes, and a history of genital warts were significantly associated with transmission. Additional factors associated with transmission that approached significance included a higher maternal virus load at delivery and the presence of cocaine in the urine. In a logistic regression model, histologic chorioamnionitis was the only independent predictor of transmission. Despite a significantly higher transmission rate at one site, no unique viral genotype was found at any site. Thus, chorioamnionitis was found to be the major risk factor for transmission among women receiving zidovudine.

Page Thumbnails

  • Thumbnail: Page 
319
    319
  • Thumbnail: Page 
320
    320
  • Thumbnail: Page 
321
    321
  • Thumbnail: Page 
322
    322
  • Thumbnail: Page 
323
    323
  • Thumbnail: Page 
324
    324
  • Thumbnail: Page 
[325]
    [325]
  • Thumbnail: Page 
326
    326
  • Thumbnail: Page 
327
    327
  • Thumbnail: Page 
328
    328